SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-17-000981
Filing Date
2017-12-01
Accepted
2017-12-01 12:39:59
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLCSAMUEL D. ISALY

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss69946_sc13d.htm SC 13D 109716
2 JOINT FILING AGREEMENT ss69946_ex9901.htm EX-99.1 9730
  Complete submission text file 0000947871-17-000981.txt   121015
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01830
Business Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01830 617-517-0730
scPharmaceuticals Inc. (Subject) CIK: 0001604950 (see all company filings)

IRS No.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90193 | Film No.: 171233400
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1